Publications by authors named "Ravin Garg"

Claim this Profile
P
Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care.
Hedyeh Ebrahimi, Jodie Allen, Yelak Biru, Ravin Garg, Christine Hodgdon

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical resection of late extrahepatic metastasis of hepatocellular carcinoma 11 years after initial diagnosis: case report and literature review.
Carolina Baz, Richard Nudotor, Bussey Ian, Ravin Garg, Glen Gibson

J Surg Case Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Acute Myeloid Leukemia in the Community Setting.
Taha Al-Juhaishi, Servillano Dela Cruz, Rohan Gupta, Gina Keiffer, Vicki A Morrison, Ravin Garg

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent - and -Mediated Resistance to Osimertinib in -Mutant NSCLC: A Case Report.
Muneeb Rehman, Chul Kim, Joshua E Reuss, Lesli A Kiedrowski, Ravin J Garg

JCO Precis Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Composite Component Behavior Using Element Level Crashworthiness Tests, Finite Element Analysis and Automated Parametric Identification.
Ravin Garg, Iman Babaei, Davide Salvatore Paolino, Lorenzo Vigna, Lucio Cascone

Materials (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ophthalmic manifestations of leukemia.
Katherine E Talcott, Ravin J Garg, Sunir J Garg

Curr Opin Ophthalmol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.
Ravin Garg, William Wierda, Alessandra Ferrajoli, Lynne Abruzzo, Sherry Pierce

Cancer· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental therapeutics for patients with myeloproliferative neoplasias.
Meetu Agrawal, Ravin J Garg, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Cancer· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
Meetu Agrawal, Ravin J Garg, Hagop Kantarjian, Jorge Cortes

Curr Oncol Rep· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine kinase inhibitors: the first decade.
Meetu Agrawal, Ravin J Garg, Jorge Cortes, Alfonso Quintás-Cardama

Curr Hematol Malig Rep· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Ravin J Garg, Hagop Kantarjian, Susan O'Brien, Alfonso Quintás-Cardama, Stefan Faderl

Blood· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
Ravin Garg, Hagop Kantarjian, Deborah Thomas, Stefan Faderl, Farhad Ravandi

Cancer· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis